查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1145990

胃气球市场：COVID-19 的增长、趋势、影响和预测（2022-2027 年）

Gastric Balloons Market - Growth, Trends, and Forecasts (2022 - 2027)
出版日期: | 出版商: Mordor Intelligence | 英文 114 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

预计胃球囊市场在预测期内的复合年增长率为 9.5%。

COVID-19 疫情对所研究的市场产生了重大影响，因为世界各国政府采取了社会疏离措施，医院和医疗保健服务受到了严重限制。例如，2021 年 2 月发表的《当大流行病相撞：COVID-19 对儿童肥胖症的影响》发现，儿童肥胖症在美国的年轻人中已经上升到大流行水平，其中重症病例上升最快肥胖。被注意到已经被看到。还有人指出，肥胖的人有患严重 COVID-19 的风险，因为体重过重会降低个体的免疫反应。 COVID-19 流行期间肥胖患者的增加可能会促进分析期间的市场增长。因此，COVID-19 对所研究的市场产生了显着影响。

此外，肥胖患病率的上升和对微创手术的需求不断增加正在对所研究市场的增长产生积极影响。

根据联合国 2022 年 3 月的文章，2022 年全球将有超过 10 亿人肥胖，其中包括 6.5 亿成年人、3.4 亿青少年和 3900 万儿童。这个数字还会增加。世界卫生组织预测，到 2025 年，大约 1.67 亿人将因超重或肥胖而变得不健康。被诊断患有肥胖症并有糖尿病和高血压等健康风险的患者可以选择接受胃球囊手术。肥胖患病率上升是胃球囊市场的主要驱动因素。

此外，产品批准、发布、合作伙伴关係和收购预计将推动市场增长。例如，2020 年 7 月，Allurion Technologies 进入亚洲市场，在香港、马来西亚和新加坡推出了 Elipse 胃气球减肥计划。向亚洲扩张，迄今为止，该地区获得无创减肥治疗的机会有限，预计该地区超过 10 亿超重或肥胖人群将受益。预计此类举措将进一步推动市场增长。

因此，由于上述因素，预计研究中的市场将在分析期间呈现增长。然而，报销政策的不足以及与胃球囊相关的副作用和并发症可能会阻碍市场增长。

主要市场趋势

预计三胃气球市场将在预测期内占据主导地位

三重胃气球系统是一种非手术治疗，可放置三个气球以实现最佳减肥效果。 Ovalon Balloon 是唯一获得 FDA 批准的三重胃气球或设备，可帮助您减轻体重，它通过占用您的胃部空间来发挥作用。 Ovalon 气球通过吞下附在小软管上的胶囊被输送到胃部，并在专家领导的营养和锻炼计划中使用六个月。

肥胖是一种慢性疾病，其中过多的脂肪组织在体内积聚，从而对健康产生不利影响。根据世界卫生组织 (WHO) 2021 年 6 月更新的数据，到 2020 年，将有大约 3900 万五岁以下儿童超重或肥胖。据报导，肥胖症在人群中呈上升趋势，因此有望推动这一细分市场的增长。

批准和发布是该细分市场增长的主要驱动力。例如，2021 年 10 月，Spatz Medical 获得了食品和药物管理局对 Spatz3 胃气球的批准，这是首批可调节胃气球之一。预计这些批准将增加对胃球囊的需求并增加细分市场的增长。

因此，由于上述因素，预计三重胃气球段在预测期内将出现增长。

预计在预测期内北美将主导胃球囊市场

北美的特点是肥胖发病率上升、老年人口不断增长、该地区行业参与者的强大存在、更好的医疗保健基础设施、公共和医疗保健行业对可用技术的看法、美国市场预计将主导市场由于参与者高度集中等因素。

2022 年 1 月发表的研究论文《社区居住成人 1 年和 3 岁肥胖发病率：一项基于人群的研究》发现，美国有 40,390 人参与了该研究并有后续数据。大多数其中40至69岁的成年人（47.5%）和女性（59.8%），其中21,379人属于超重组。肥胖的患病率在 1 年时为 7%，在 3 年时为 16%。另据报导，40 至 69 岁的男性和 20 至 39 岁的女性分别在 1 年和 3 年后发生肥胖的比率最高。预计该地区肥胖人数的增加将提振对治疗性胃球囊手术的需求，从而推动该地区的市场增长。

越来越多的产品发布、合作伙伴关係、合併、收购和政府举措（尤其是在美国）正在推动市场增长。例如，2021 年 3 月，Apollo Endosurgery, Inc. 宣布了一项适应症，用于治疗基础代谢指数 (BMI) 为 30-40 kg/m2 的肝纤维化非切口非酒精性脂肪性肝炎 (NASH) 患者. orbera 胃内气球已获得美国食品和药物管理局的突破性设备指定。因此，预计这样的推出将增加该地区胃气球的使用并促进市场增长。

此外，2021 年 1 月，ReShape Lifesciences Inc. 与 Obalon Therapeutics, Inc. 签订了合併协议。根据协议条款，Obalon 更名为 ReShape Lifesciences Inc.。两家公司都生产减肥技术和解决方案。预计合併将导致该地区研究市场的增长。

因此，由于上述因素，预计北美市场将扩大。

竞争格局

由于存在少数在全球和地区运营的公司，胃球囊市场适度整合。竞争格局包括对具有市场份额的知名国际和本地公司的分析。其中包括 ReShape Lifesciences, Inc.、Allurion Technologies, Inc.、Apollo Endosurgery, Inc.、Districlass Medical、Helioscopie Medical Implants 和 Silimed, Inc.。 LEXEL S.R.L.、Medispar cvba、Spatz Cosmeceutical Inc.、ENDALIS 等。

其他福利。

  • Excel 格式的市场预测 (ME) 表
  • 三个月的分析师支持

内容

第一章介绍

  • 研究假设和市场定义
  • 调查范围

第二章研究方法

第 3 章执行摘要

第 4 章市场动态

  • 市场概览
  • 市场驱动力
    • 肥胖患病率上升
    • 对微创手术的需求增加
  • 市场製约因素
    • 兑换政策不佳
    • 与胃膨胀有关的副作用或併发症
  • 波特五力分析
    • 新进入者的威胁
    • 买方/消费者议价能力
    • 供应商的议价能力
    • 替代品的威胁
    • 竞争公司之间的敌对关係

第 5 章市场细分（基于价值的市场规模：100 万美元）

  • 按产品类型
    • 单胃气球
    • 双气化气球
    • 三重胃气球
  • 通过填充材料
    • 充满盐水的气球
    • 充气气球
  • 按插入方式
    • 内窥镜
    • 口语
  • 按地区
    • 北美
      • 美国
      • 加拿大
      • 墨西哥
    • 欧洲
      • 德国
      • 英国
      • 法国
      • 意大利
      • 西班牙
      • 其他欧洲地区
    • 亚太地区
      • 中国
      • 日本
      • 印度
      • 澳大利亚
      • 韩国
      • 其他亚太地区
    • 中东和非洲
      • 海合会
      • 南非
      • 其他中东
    • 南美洲地区
      • 巴西
      • 阿根廷
      • 其他南美洲

第 6 章竞争格局

  • 公司简介
    • Reshape Lifesciences Inc
    • Allurion Technologies Inc.
    • Apollo Endosurgery, Inc.
    • Districlass Medical SA
    • Helioscopie Medical Implants
    • Silimed, Inc.
    • Medispar cvba
    • Spatz Cosmeceutical Inc.
    • ENDALIS
    • LEXEL S.R.L

第7章 市场机会今后动向

简介目录
Product Code: 67636

The gastric balloon market is expected to register a CAGR of 9.5% over the forecast period.

The COVID-19 outbreak had a significant impact on the studied market as hospital and healthcare services were significantly reduced due to social distancing measures taken by governments across the world. For instance, an article titled "When Pandemics Collide: The Impact of COVID-19 on Childhood Obesity" published in February 2021 indicated that the disease of childhood obesity had risen to pandemic levels in United States youth with the fastest rise seen in severe obesity. The article also indicated that obese people were at risk for severe COVID-19, as excess weight decreases an individual's immune response. The increase in obesity cases during the COVID-19 pandemic is likely to enhance the market growth in the analysis period. Hence, COVID-19 had a pronounced impact on the studied market.

In addition, the rising prevalence of obesity and increasing demand for minimally invasive surgeries are actively affecting the growth of the studied market.

According to United Nations March 2022 article, more than one billion people worldwide are obese in 2022, including 650 million adults, 340 million adolescents, and 39 million children and the numbers are likely to rise. The World Health Organization predicted that by 2025, roughly 167 million people are projected to become less healthy due to being overweight or obese. Patients diagnosed with obesity and associated health risks such as diabetes and hypertension are given the option to undergo a gastric balloon procedure. The rising prevalence of obesity is the key driving factor in the gastric balloon market.

Furthermore, product approvals, launches, partnerships, and acquisitions are expected to propel market growth. For instance, in July 2020 Allurion Technologies expanded into the Asian market with the launch of the Elipse Gastric Balloon Weight Loss Program in Hong Kong, Malaysia, and Singapore. Over 1 billion overweight or obese people in the region were expected to benefit from the company's entry into Asia, a region that has previously had limited access to non-invasive weight loss treatments. Such initiatives are projected to further boost the market growth.

Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period. However, poor reimbursement policies and side effects or complications associated with gastric balloons may impede the market growth.

Key Market Trends

Triple Gastric Balloons Segment is Expected to to Dominate Over the Forecast Period

A triple gastric balloon system is a non-surgical treatment in which three balloons are placed for optimal weight loss. Obalon balloon is the only Food and Drug Administration-approved triple gastric balloon or device that helps in weight loss and works by taking up space in the stomach. Obalon balloon is delivered into the stomach by swallowing a capsule connected to a small bendable tube for six months combined with a professionally supervised nutrition and exercise program.

Obesity is a chronic disease characterized by excessive adipose tissue accumulation in the body, resulting in adverse health effects. Data provided by World Health Organization (WHO) updated in June 2021 indicated that there were around 39 million children under the age of five, who were overweight or obese in the year 2020. It also reported that there is steep rise in obesity among the population and thus it is expected to boost the segment's growth.

The approvals and launches are primary drivers of the segment's growth. For instance, in October 2021, Spatz Medical received the Food and Drug Administration approval for the Spatz3 Gastric Balloon, one of the first adjustable gastric balloons. These approvals are projected to increase the demand for gastric balloons and augment segment growth.

Therefore, owing to the above mentioned factors, the triple gastric balloons segment is expected to show growth over the forecast period.

North America is Expected to Dominate the Gastric Balloons Market Over the Forecast Period

North America is expected to dominate the market owing to factors such as the rising incidence of obesity, growing geriatric population, the strong presence of industry players in the region, better healthcare infrastructure, awareness among people and healthcare industry stakeholders about available technologies, and the high concentration of market players in the United States.

The research article titled "Incidence of Obesity at 1 and 3 Years Among Community-Dwelling Adults: A Population-Based Study" published in January 2022 stated that the majority of the 40,390 people in the United States who were part of the study and had follow-up data were adults aged 40 to 69 (47.5%), female (59.8%), and 21,379 (52.8%) of them fell into the overweight weight group. Obesity prevalence was 7% after one year and 16% after three years of follow-up. It also reported that the age groups of males aged 40 to 69 and women aged 20 to 39 had the largest percentages of those who developed obesity after one and three years of follow-up respectively. The increase in obesity in the region is expected to increase the demand for gastric balloon procedures for treatment and thus boost the market growth in the region.

The increasing product launches, partnerships, mergers, acquisitions, and government initiatives particularly in the United States are leading to an increase in market growth. For instance, in March 2021, Apollo Endosurgery, Inc. received a breakthrough device designation from the United States Food and Drug Administration for the orbera intragastric balloon, with a focus on the indication for use in treating patients with noncirrhotic nonalcoholic steatohepatitis (NASH) with liver fibrosis and a basal metabolic index (BMI) between 30 and 40 kg/m2. Hence, such launches are expected to increase the usage of gastric balloons in the region and augment market growth.

Additionally, in January 2021 ReShape Lifesciences Inc. signed a merger agreement with Obalon Therapeutics, Inc. Under the agreement terms, Obalon was renamed ReShape Lifesciences Inc. Both companies are involved in producing weight-loss technologies and solutions. The merger is anticipated to lead to growth in the studied market in the region.

Therefore, owing to the above-mentioned factors, the growth of the studied market is anticipated in the North America region.

Competitive Landscape

The Gastric balloon market is moderately consolidated due to the presence of a few companies operating globally as well as regionally. The competitive landscape includes an analysis of a few international and local companies that hold market shares and are well known. Some of the companies are ReShape Lifesciences, Inc., Allurion Technologies, Inc., Apollo Endosurgery, Inc., Districlass Medical, Helioscopie Medical Implants, Silimed, Inc. , LEXEL S.R.L, Medispar cvba, and Spatz Cosmeceutical Inc., and ENDALIS among others.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Prevalence of Obesity
    • 4.2.2 Increasing Demand for Minimally Invasive Surgeries
  • 4.3 Market Restraints
    • 4.3.1 Poor Reimbursement Policies
    • 4.3.2 Side Effects or Complications Associated with Gastric Balloons
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Product Type
    • 5.1.1 Single Gastric Balloons
    • 5.1.2 Dual Gastric Balloons
    • 5.1.3 Triple Gastric Balloons
  • 5.2 By Filling Material
    • 5.2.1 Saline Filled Balloons
    • 5.2.2 Gas Filled Balloons
  • 5.3 By Insertion Method
    • 5.3.1 Endoscopic
    • 5.3.2 Oral
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East and Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle East and Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Reshape Lifesciences Inc
    • 6.1.2 Allurion Technologies Inc.
    • 6.1.3 Apollo Endosurgery, Inc.
    • 6.1.4 Districlass Medical SA
    • 6.1.5 Helioscopie Medical Implants
    • 6.1.6 Silimed, Inc.
    • 6.1.7 Medispar cvba
    • 6.1.8 Spatz Cosmeceutical Inc.
    • 6.1.9 ENDALIS
    • 6.1.10 LEXEL S.R.L

7 MARKET OPPORTUNITIES AND FUTURE TRENDS